Paragon 28 Inc (N:FNA)
Business Focus: Medical Equipment, Supplies & Distribution
Apr 04, 2024 08:01 am ET
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024
Paragon 28, Inc. (NYSE: FNA), (“Paragon 28” or “the Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Stephen Deitsch, Chief Financial Officer (“CFO”), has notified the Company of his intent to pursue an opportunity with OrganOx Limited, a commercial stage UK-based medical device company focused on therapeutic applications of isolated organ perfusion. Mr. Deitsch will depart from the Company on April 5, 2024. The Company has formed a sub-committee of its Board of Directors and has engaged an executive search firm to as
Mar 28, 2024 04:05 pm ET
Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains.
Feb 29, 2024 04:05 pm ET
Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance.
Feb 12, 2024 11:36 am ET
Paragon 28 to Present at the CG 2024 Musculoskeletal Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the CG 2024 Musculoskeletal Conference on Monday, February 12, 2024, at 1:00 p.m. Pacific Time / 2:00 p.m. Mountain Time.
Feb 06, 2024 04:05 pm ET
Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.
Feb 01, 2024 08:00 am ET
Paragon 28 Launches PRECISION® MIS Bunion System Offering Surgeons a Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique.
Jan 30, 2024 04:43 pm ET
Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures
Paragon 28, Inc. (NYSE: FNA) is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System designed for a wide range of minimally invasive and open procedures in the foot and ankle.
Jan 26, 2024 08:00 am ET
Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Mister Tendon™ System which allows surgeons to perform a distal cut of the flexor hallucis longus (“FHL”) or flexor digitorum longus (“FDL”) tendon through a minimally invasive incision, harvesting a working length of tendon suitable for tendon transfer procedures. Use of this instrumentation through a minimally invasive approach, is designed to allow for better healing and quicker recovery time in flatfoot reconstruction. In addition to the harvester, an accessory dilator instrument is provided to help bluntly dissect soft
Jan 17, 2024 08:00 am ET
Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures
Paragon 28, Inc. (NYSE: FNA), is excited to announce the limited market release of its Bun-Yo-Matic™ Lapidus Clamp System and completion of the first surgical cases in Orange County, California and Seattle, Washington. The Bun-Yo-Matic™ is the only bunion solution on the market designed to intraoperatively simulate weight-bearing and allow for compression prior to hardware application. This unique approach provides surgeons a more reproducible and efficient means to restore three-dimensional alignment of the foot while accommodating each surgeon’s preferred fixation methodology in a Lapidus pr
Jan 08, 2024 09:00 am ET
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023.
Jan 05, 2024 08:00 am ET
Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape
Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch of the Grappler® Knotless Anchor System and Bridgeline™ Tape, enhancing the Company’s position in the fast-growing foot and ankle specific soft tissue market in 2024 and beyond. Both the Grappler® Knotless Anchor System and Bridgeline™ Tape are highly complementary to a broad range of Paragon 28’s existing hardware products with several applications spanning multiple foot and ankle indications.
Dec 19, 2023 04:05 pm ET
Paragon 28 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 p.m. Pacific Time / 4:00 p.m. Mountain Time.
Nov 14, 2023 04:05 pm ET
Paragon 28 Launches BEAST™ Cortical Fibers Expanding its Biologics Portfolio
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its BEAST™ Cortical Fibers which provide an osteoinductive porous structure for cellular attachment and an osteoinductive potential to aid in cellular differentiation and bone formation. These loose cortical fibers are engineered to complement specific surgical applications in the foot and ankle and are flexible upon hydration allowing for application even in extremely challenging fusion locations. The cortical matrix absorbs bioactive fluid including bone marrow aspirate and supports cellular infiltration to drive efficient bon
Nov 14, 2023 08:00 am ET
Paragon 28 Launches JAWS™ Great White Staple System Further Expanding its Nitinol Staple Offering
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its JAWS™ Great White Staple System which was developed to provide for increased strength and stability of the osteotomy or fusion site when compared to traditional staple systems. The staples feature an ultra-low-profile bridge with increased surface area to enhance stability while minimizing soft tissue irritation. The newly designed staple has 400 times the fatigue life compared to a competitive nitinol staple subjected to the same load parameters.1 The shoulders of the staple work in conjunction with the inserter
Nov 13, 2023 04:05 pm ET
Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the addition of a second trailer to its nationwide mobile lab training program making it even more convenient for the company to facilitate on-site surgeon training and education. Paragon 28’s new mobile lab is housed in a 40 foot tractor-trailer which includes a state-of-the-art, 5 station, cadaveric training facility accommodating up to 25 surgeons. The mobile lab will host over 70 training sessions in approximately 65 US cities during quarter four of 2023. The mobile lab program kicked off in July of 2022 and has been an incredible success
Nov 07, 2023 04:05 pm ET
Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that it has received a new $150 million credit facility from Ares Capital Corporation (“the Facility”) to replace its existing $90 million senior credit facility. The Facility is comprised of up to $100 million in term loans, with $75 million drawn at close, and a $50 million revolving credit facility, with $25 million drawn at close. The Facility is non-dilutive without warrants or other equity-based instruments. The Company’s
Nov 07, 2023 04:05 pm ET
Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance.
Nov 03, 2023 08:00 am ET
Paragon 28 to Present at Upcoming Investor Conferences
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting in fireside chats at two upcoming investor conferences. Paragon 28 will participate in the Stephens Annual Investment Conference on November 15, 2023, and the 35th Annual Piper Sandler Healthcare Conference on November 28, 2023.
Oct 17, 2023 04:05 pm ET
Paragon 28 To Report Third Quarter Financial Results on November 7, 2023
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.
Sep 11, 2023 07:00 am ET
Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System
Paragon 28, Inc. (NYSE: FNA), announced today they have received an Investigational Device Exemption (IDE) approval from the FDA to commence a feasibility study for configurations of the SMART Total Talus™ System used in conjunction with the Paragon 28® APEX 3D™ Total Ankle Replacement System. The study is expected to begin in early 2024.
Aug 28, 2023 04:05 pm ET
Paragon 28 to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 4:55 p.m. Eastern Time / 2:55 p.m. Mountain Time.
Aug 02, 2023 04:05 pm ET
Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance.
Jul 28, 2023 08:00 am ET
Paragon 28 to Present at the Canaccord Genuity 43rd Annual Growth Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time.
Jul 12, 2023 04:05 pm ET
Paragon 28 To Report Second Quarter Financial Results on August 2, 2023
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.
May 23, 2023 08:00 am ET
Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its Gorilla® Supramalleolar Osteotomy (SMO) Plating and PRESERVE™ SMO Allograft System which were developed to provide surgeons versatility in plate selection and surgical approach for supramalleolar osteotomies. The system includes patent pending drilling and cutting guides to facilitate repeatable and controlled anterior dome, medial opening, and closing wedge osteotomies. The system also includes a patent pending allograft cutting jig designed to shape the PRESERVE™ SMO Allograft Wedge to match the intended correction while r
May 04, 2023 04:05 pm ET
Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue guidance.
Apr 26, 2023 04:05 pm ET
Paragon 28 to Present at the Bank of America Securities 2023 Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 5:20 p.m. Eastern Time / 3:20 p.m. Mountain Time.
Apr 24, 2023 04:05 pm ET
Paragon 28 Launches Phantom® Metatarsal Shortening System
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of its Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of the lesser metatarsals. These osteotomies are preformed to prevent metatarsalgia and floating toe, two of the most frequently addressed foot and ankle pathologies. The system includes a patent pending cut guide allowing for increased precision when performing the correction.
Apr 20, 2023 04:05 pm ET
Paragon 28 To Report First Quarter Financial Results on May 4, 2023
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.
Mar 02, 2023 04:05 pm ET
Paragon 28 Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2022.
Mar 01, 2023 04:05 pm ET
Paragon 28 to Present at Upcoming Investor Conferences
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will be presenting in fireside chats at two upcoming investor conferences. Paragon 28 will participate in the CG 2023 Musculoskeletal Conference on March 7th, 2023, and the 22nd Annual Needham Virtual Healthcare Conference on April 19th, 2023.
Feb 17, 2023 02:00 pm ET
Paragon 28, Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today completion of the sale of an additional 975,000 shares of its common stock, pursuant to the exercise in full of the option to purchase additional shares granted to the underwriters in connection with Paragon’s recently completed underwritten public offering of 6,500,000 shares of common stock, at a public offering price of $17.00 per share, before underwriting discounts and commissions. 562,500 shares were sold by Paragon and 412,500 shares wer
Feb 16, 2023 04:05 pm ET
Paragon 28 To Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, March 2, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Jan 25, 2023 10:47 pm ET
Paragon 28, Inc. Announces Pricing of Public Offering
Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions. 3,750,000 shares in the offering are being offered for sale by Paragon and 2,750,000 shares are being offered for sale by certain selling securityholders. In addition, Paragon and the selling securityholders have granted the underwriters a 30-d
Jan 25, 2023 04:20 pm ET
Paragon 28, Inc. Announces Proposed Public Offering of Common Stock
Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the commencement of a proposed underwritten public offering of 6,500,000 shares of its common stock, consisting of 3,750,000 shares offered by Paragon and 2,750,000 shares offered by certain selling securityholders. Paragon and the selling securityholders also expect to grant the underwriters a 30-day option to purchase up to an additional 562,500 and 412,500 shares of common stock, respectively. The proposed offering is subject to market and o
Jan 10, 2023 06:00 am ET
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2022.
Nov 16, 2022 04:05 pm ET
Paragon 28 to Present at The 34th Annual Piper Sandler Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
Nov 10, 2022 04:02 pm ET
Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2022 and increased its 2022 net revenue guidance.
Oct 27, 2022 04:02 pm ET
Paragon 28 To Report Third Quarter 2022 Financial Results on November 10, 2022
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 10, 2022. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Aug 25, 2022 04:02 pm ET
Paragon 28 to Present at The Morgan Stanley 20th Annual Global Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will be presenting at the Morgan Stanley 20th Annual Global Healthcare Conference. Mr. DaCosta and Mr. Deitsch will be hosting a fireside chat presentation on Tuesday, September 13th, 2022, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.
Aug 04, 2022 08:00 am ET
Paragon 28 Announces Changes to its Board of Directors
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced two changes to the composition of its Board of Directors.
Aug 03, 2022 04:02 pm ET
Paragon 28 Reports Second Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2022 and increased its 2022 revenue guidance.
Jul 18, 2022 08:00 am ET
Paragon 28 to Present at The Canaccord Genuity 42nd Annual Growth Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting at The Canaccord Genuity 42nd Annual Growth Conference in Boston. The Canaccord Genuity fireside chat will be webcast live on August 11, 2022, at 1:00pm Eastern Time.
Jul 18, 2022 08:00 am ET
Paragon 28 To Report Second Quarter 2022 Financial Results on August 3, 2022
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Jul 13, 2022 08:00 am ET
Paragon 28 Launches Mobile Medical Education Lab Tour, Expanding Opportunities for Foot and Ankle Surgeon Education
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced its new nationwide mobile training lab tour, for convenient, on-site surgeon training and education.
Jun 09, 2022 08:00 am ET
Paragon 28 Launches Monkey Rings™ Circular External Fixation System
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the launch of its Monkey Rings™ Circular External Fixation System for trauma, deformity correction, and limb salvage.
May 19, 2022 08:00 am ET
Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The TenoTac™ 2.0 Soft Tissue Fixation System uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surface.
May 17, 2022 08:00 am ET
Paragon 28 Expands Soft Tissue Portfolio with Grappler™ Suture Anchor System Launch
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grappler™ Suture Anchor System. The Grappler™ Suture Anchor System provides surgeons an alternative fixation option designed to limit implant migration and loss of tension for intraoperative tissue reattachment and fixation in the foot and ankle.
May 09, 2022 04:02 pm ET
Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2022 and updated its 2022 revenue guidance.
Apr 27, 2022 08:00 am ET
Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammertoe and soft-tissue portfolio with the launch of its Paratrooper™ Plantar Plate Repair System. The Paratrooper™ Plantar Plate System’s low profile, all-suture implant provides surgeons a new and innovative approach for plantar plate repair and forefoot deformities.
Apr 19, 2022 08:00 am ET
Paragon 28 Launches R3ACT™ Stabilization System for Ankle Injuries
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the launch of its R3ACT™ Stabilization System, designed to be a simple solution that allows for multi-stage soft tissue healing following an acute or chronic syndesmotic injury to the ankle.
Apr 18, 2022 04:03 pm ET
Paragon 28 To Report First Quarter 2022 Financial Results on May 9, 2022, and Present at the 2022 Bank of America Healthcare Conference on May 10, 2022
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Mar 28, 2022 04:02 pm ET
Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board’s Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon
Mar 10, 2022 08:00 am ET
Paragon 28 to Present at Upcoming Canaccord Genuity Musculoskeletal Conference and Needham Healthcare Conference
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting at the Canaccord Genuity Musculoskeletal Conference on March 22nd and 2022 Needham Healthcare Conference on April 11th.
Mar 08, 2022 04:01 pm ET
Paragon 28 Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and twelve months ended December 31, 2021.
Feb 17, 2022 08:00 am ET
Paragon 28 to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 8, 2022. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Jan 12, 2022 07:00 am ET
Paragon 28 Announces Acquisition of Disior
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the acquisition of Disior Oy., a leading three-dimensional analytics pre-operative planning software company based in Helsinki, Finland, focused on the complex foot and ankle anatomy.
Jan 10, 2022 06:00 am ET
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2021.
Dec 29, 2021 07:00 am ET
Paragon 28, Inc. R3ACT™ Stabilization System Cleared by FDA
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its R3ACT™ Stabilization System. The R3ACT™ Stabilization System, expected to commercially launch in early 2022, will complement Paragon 28’s comprehensive ankle fracture and soft tissue portfolio and further expands Paragon 28’s product offering in the foot and ankle space.
Dec 16, 2021 07:00 am ET
Paragon 28 to Present at 24th Annual Needham Growth Conference
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will virtually present at the 24th Annual Needham Growth Conference on Monday, January 10th.
Dec 13, 2021 04:01 pm ET
Paragon 28’s Patient Specific Titanium Talus Spacer Has Been Approved by the U.S. Food and Drug Administration
Paragon 28, Inc. (NYSE: FNA) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufactured in titanium alloy with a titanium nitride coat
Dec 01, 2021 07:00 am ET
Paragon 28 Announces Addition of B. Kristine Johnson and Kristina Wright to its Board of Directors
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of B. Kristine Johnson and Kristina Wright to the Board of Directors, effective December 1, 2021.
Nov 22, 2021 08:01 am ET
Paragon 28 to Present at Piper Sandler 33rd Annual Healthcare Conference
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will virtually present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will also be hosting virtual investor meetings on November 30 and December 1.
Nov 22, 2021 08:00 am ET
Paragon 28 Reports Third Quarter 2021 Financial Results and Provides 2021 Fourth Quarter Net Revenue Guidance
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and nine months ended September 30, 2021.
Nov 15, 2021 04:13 pm ET
Paragon 28, Inc. Circular External Fixation System Cleared by FDA
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced today that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its Circular External Fixation System. The Circular External Fixation System, expected to commercially launch in early 2022, will complement Paragon 28’s comprehensive internal fixation portfolio and further expands Paragon 28’s product offering in the foot and ankle space.
Nov 10, 2021 04:05 pm ET
Paragon 28 To Report Third Quarter 2021 Financial Results on November 22, 2021
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter of 2021 before market open on Monday, November 22, 2021. The company’s management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time.
Oct 15, 2021 05:52 pm ET
Paragon 28, Inc. Announces Pricing of Initial Public Offering
ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ -- Paragon 28, Inc. (NYSE: FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by PARAGON. PARAGON's common stock is expected to begin trading on the New York Stock Exc
Oct 14, 2021 10:35 pm ET
Paragon 28, Inc. Announces Pricing of Initial Public Offering
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by PARAGON. PARAGON’s common stock is expected to begin trading on the New York Stock Exchange on October 15, 2021, under the ticker symbol
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.